Agnes Mwakingwe-Omari

6PUBLICATIONS
19CO-AUTHORS
Pacific Peoples life courseDisease surveillanceEpidemiological methodsInnate immunityNutritional epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 05, 2026
Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 Years.

|Apr 10, 2026
Age-specific Risk of Herpes Zoster in Immunocompetent Adults ≥18 Years-of-age-A Retrospective Cohort Study in the United States.

Rachel A Cohen, Driss Oraichi, Agnes Mwakingwe-Omari

|Mar 26, 2026
Age-Specific Risk of Herpes Zoster in Adults Aged ≥18 Years With Comorbid Conditions-A Retrospective Cohort Study in the United States.

Rachel A Cohen, Driss Oraichi, Agnes Mwakingwe-Omari

|Mar 21, 2024
No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial.

Abdi Naficy, Adrienne Kuxhausen, Harry Seifert

|Nov 15, 2023
Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.

Agnes Mwakingwe-Omari, Nicolas Lecrenier, Abdi Naficy

|Jun 19, 2023
No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial.

Abdi Naficy, Adrienne Kuxhausen, Paola Pirrotta

Pageof 1

Frequent Collaborators

3 joint publications

Abdi Naficy

2 joint publications

Adrienne Kuxhausen

2 joint publications

Brett Leav

2 joint publications

Jacqueline Miller